Showing results (31-40 of 374) with videos related to
Sort By:
Pageof 38
Seminars in Oncology|December 11, 2007
Clinical benefits and considerations of bisphosphonate treatment in metastatic bone diseaseFred Saad, Allan LiptonCurrent Opinion in Supportive and Palliative Care|August 10, 2011
Denosumab: benefits of RANK ligand inhibition in cancer patientsAllan Lipton, Ira JacobsOncology Reports|October 11, 2002
Restoration of estrogen responsiveness by blocking the HER-2/neu pathwayLois Witters, Linda Engle, Allan LiptonWomen'S Health (London, England)|October 7, 2009
Managing aromatase inhibitor-associated bone loss in breast cancerAllan Lipton, Michael Gnant, Matti AaproCancer|August 28, 2003
Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinomaAllan Lipton, Ming Zheng, John SeamanSupportive Cancer Therapy|July 18, 2008
Role of bisphosphonates for the management of skeletal complications and bone pain from skeletal metastasesLuis Costa, Allan Lipton, Robert E ColemanClinical Orthopaedics and Related Research|November 6, 2003
Biochemical markers and skeletal metastasesLaurence M Demers, Luis Costa, Allan LiptonBreast Disease|December 7, 2011
Bone turnover markers: tools for prognosis and monitoring response to bisphosphonates?Allan Lipton, Luis Costa, Robert E ColemanOncology Reports|February 10, 2004
Combining flavopiridol with various signal transduction inhibitorsLois M Witters, Abigail Myers, Allan LiptonInternational Journal of Hematology|April 27, 2011
Treatment of Langerhans cell histiocytosis bone lesions with zoledronic acid: a case seriesShanthi Sivendran, Harold Harvey, Allan Lipton, et al.Pageof 38